Reportlinker Adds The Top 10 CMOs in India: Market Dynamics, Competitive Positioning and Trends
NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The Top 10 CMOs in India: Market dynamics, competitive positioning and trends
India offers significant cost advantages over mature manufacturing hubs in Europe and North America. Both domestic pharmas and contract manufacturers (CMOs) are moving up the value chain into process development and drug discovery services. Many have evolved into Contract Research and Manufacturing Services (CRAMS) players.
The Top 10 Indian CMOs faced a challenging business environment in the fiscal year, 2010 – most saw revenues contract on the previous year. This report analyzes each of the Top 10 CMOs in turn, reviewing growth strategies and recent deals.
Key Features
- Overview of the global contract manufacturing market
- Market dynamics of Indian CMO market
- Profile of the leading 10 players in Indian CMO/CRAMS market
- Key contract manufacturing partnerships in the Indian CMO sector
- Key trends and opportunities in Indian CMO market
- Major success factors in Indian CRAMS market
- Strategic growth analysis including SWOT profiles of leading 10 players in Indian CMO market
- Short profile of other leading players
Key Benefits
- Analyze the competitive positioning and outlook for each of the Top 10 Indian CMOs/CRAMS companies.
- Develop insights on the Indian CMO market, including market size forecast, and future outlook of global CRAMS industry and opportunities in India.
- Discover contract manufacturing deals that are shaping the development of the market.
- Learn the key factors for success in the CMO market.
- Understand the major issues affecting the Indian CMO industry.
- Assess the financial performance and growth strategies of leading companies in Indian CMO market.
Key findings
The global pharmaceutical contract manufacturing market can be categorized into injectables, solid and liquid dosage forms. Solid dosage is the largest segment by revenue, but the injectable segment is expected to show greatest growth.
Asian CMOs started with large-scale manufacturing for generic and research driven companies are now acquiring assets in the US and Europe to enter the discovery and development segment of the pharmaceutical value chain.
India, riding on its cost-value proposition comprising low-cost skilled manpower and technical capabilities is strongly positioned to capture a significant portion of the growing CMO market. The CRAMS market will continue to provide high growth opportunity and companies which offer reliable services with a significant value proposition in terms of costs and technology will succeed.
India has already emerged as one of the leading cost-competitive and quality manufacturing hubs for many global players including big pharma companies. Moreover, the current economic crisis along with the continuous pricing pressure and pro-generic agenda are driving pharma companies to leverage the strengths of Indian pharma manufacturers.
Drivers of the Indian CMO market include the high number of FDA approved manufacturing facilities, large and growing talent pool and continuing cost advantages. Resistors include intellectual property concerns, competition from China, and safety concerns.
Key questions answered by this report
- What are the key trends of Indian contract manufacturing industry?
- Which companies will drive the future of the Indian CMO market?
- What are the strengths, weaknesses, threats, and opportunities of the leading CMOs in India?
- How was the financial performance of leading players in the Indian CMO market affected by the recent economic downturn?
- Which companies are best positioned to succeed in Indian CMO market in the next five years?
- How are the growth strategies of leading Indian CMOs such as Jubilant Organosys, Dr. Reddy's, Divis Laboratories, Dishman, Piramal Healthcare, Hikal, Shasun, and Biocon evolving?
- Which are the key contract manufacturing partnerships that will shape the future of Indian CMO market?
Table of Contents
About the author 2
Disclaimer 2
Executive summary 11
Industry overview 11
Jubilant Organosys 11
Dr. Reddy's 12
AuroSource 13
Divis Laboratories 13
Dishman 14
Piramal Healthcare 15
Hikal 15
Shasun Chemicals and Drugs Limited (SCDL) 16
Biocon 17
Suven Life Sciences 17
Chapter 1 Scope 19
Scope 19
Methodology 19
Chapter 2 Industry overview 20
Summary 20
What are CMOs? 21
Structure of the CMO industry 21
CMO expansion in Asia 22
Contract manufacturing and research services in context 23
Custom synthesis 23
Contract manufacturing in pharma 24
Key success factors for CMOs 26
Value addition to end-users 26
Scientific skill-set 26
Respect for intellectual property rights 26
Cost-effectiveness 26
Strong relationship with innovators 26
The Indian CRAMS business 27
Factors impacting the growth momentum of CRAMS in India 27
India – a biopharmaceutical manufacturing hub 28
Regulatory and IP issues 29
Key contract manufacturing/research deals in India 29
Future outlook of the global CRAMS industry and opportunities for India 30
Market dynamics 32
CRAMS market size and structure 32
Competitive landscape of the Indian CMO industry 32
Drivers and resistors of Indian CMOs 34
Chapter 3 Jubilant Organosys 36
Summary 36
Company overview 37
Business segmentation 38
R&D focus 39
Financial performance 40
Growth strategies 43
Partnering with pharma and biotech clients 43
Full service provision 43
Diversified niche businesses reduce risks 43
SWOT analysis 45
Chapter 4 Dr. Reddy's 46
Summary 46
Company overview 47
Business segmentation 48
R&D focus 48
Financial performance 49
Growth strategies 50
mPEG alcohol manufacturing facility in Mexico 50
Strategic alliance with GSK for emerging markets outside India 50
SWOT analysis 51
Chapter 5 AuroSource 52
Summary 52
Company overview 53
Business segmentation 53
R&D focus 54
Financial performance 54
Growth strategies 55
Aurobindo's investment in CRAMS business 55
Diversified contract manufacturing capabilities 55
SWOT analysis 56
Chapter 6 Divis Laboratories 57
Summary 57
Company overview 58
Business segmentation 58
R&D focus 59
Financial performance 60
Growth strategies 60
Innovation driven pharma companies continue to be key clients 60
Strong chemistry skills and process development capabilities 60
Generic API business to maintain steady growth 61
SWOT analysis 62
Chapter 7 Dishman 63
Summary 63
Company overview 64
Business segmentation 65
R&D focus 65
Financial performance 66
Growth strategies 66
CRAMS business will continue to dominate 66
Dishman's Solvay operation rejuvenates with its recent acquisition by Abbott 67
High number of capacity expansions and state-of-the-art manufacturing facilities 67
SWOT analysis 68
Chapter 8 Piramal Healthcare 69
Summary 69
Company overview 70
Business segmentation 71
R&D focus 71
Financial performance 72
Growth strategies 73
Strong distribution and marketing infrastructure in India 73
Rationalization of international contract manufacturing unit to increase its efficiency 73
SWOT analysis 74
Chapter 9 Hikal 75
Summary 75
Company overview 76
Business segmentation 77
R&D focus 77
Financial performance 78
Growth strategies 78
Long-term contracts with leading life sciences companies 78
Expansion of manufacturing base by adding new plants at its FDA site 79
SWOT analysis 80
Chapter 10 Shasun Pharmaceuticals Limited 81
Summary 81
Company overview 82
Business segmentation 82
R&D focus 83
Financial performance 84
Growth strategies 85
Manufacturing higher quantities of existing products 85
Integrating CRAMS offering across geographies 85
SWOT analysis 86
Chapter 11 Biocon 87
Summary 87
Company overview 88
Business segmentation 89
R&D focus 89
Financial performance 90
Growth strategies 90
Strong manufacturing capabilities in wide range of segments 90
R&D collaboration with Bristol-Myers Squibb 91
Biopharmaceutical revenues to maintain steady growth in coming years 91
SWOT analysis 92
Chapter 12 Suven Life Sciences 93
Summary 93
Company overview 94
Business segmentation 94
R&D focus 95
Financial performance 96
Growth strategies 96
Certified facilities to cater for the needs of global pharmaceutical companies 96
Dedicated pharmaceutical product services in the form of Suven Nishtaa 96
SWOT analysis 97
Chapter 13 Other key players 98
Summary 98
Lupin (Novodigm) 99
Company overview 99
Recent financial performance 99
Intas 100
Company overview 100
Recent financial performance 101
Ranbaxy (under Daiichi Sankyo) 101
Company overview 101
Recent financial performance 102
Wockhardt 102
Company overview 103
Recent financial performance 103
Strides Arcolab 104
Company overview 104
Recent financial performance 104
Appendix 106
Glossary 106
Table of figures
Figure 1: Factors influencing manufacturing outsourcing in India 25
Figure 2: Drivers and resistors of Indian CMOs 35
Figure 3: Jubilant Organosys business segmentation 38
Figure 4: Jubilant Organosys SWOT analysis 45
Figure 5: Dr. Reddy's business segmentation 48
Figure 6: Dr. Reddy's SWOT analysis 51
Figure 7: AuroSource SWOT analysis 56
Figure 8: Divis Laboratories SWOT analysis 62
Figure 9: Dishman SWOT analysis 68
Figure 10: Piramal Healthcare SWOT analysis 74
Figure 11: Hikal SWOT analysis 80
Figure 12: Shasun SWOT analysis 86
Figure 13: Biocon SWOT analysis 92
Figure 14: Suven SWOT analysis 97
Table of Tables
Table 1: Key contract manufacturing or research deals in India, 2007–10 30
Table 2: Indian contract manufacturing market size forecast ($bn), 2009–15 32
Table 3: Leading 10 CMOs/CRAMS players in India, FY 2010 33
Table 4: Jubilant Organosys snapshot 37
Table 5: Jubilant Organosys financial performance by segment ($m), FY 2010 41
Table 6: Jubilant Organosys pharma services financial performance by segment ($m), FY 2010
41
Table 7: Jubilant Organosys CRAMS financial performance by segment ($m), FY 2010 42
Table 8: Dr. Reddy's snapshot 47
Table 9: Dr. Reddy's financial performance by segment ($m), FY 2010 49
Table 10: AuroSource snapshot 53
Table 11: Divis Laboratories snapshot 58
Table 12: Dishman snapshot 64
Table 13: Dishman financial performance by segment ($m), FY 2010 66
Table 14: Piramal Healthcare snapshot 70
Table 15: Piramal Healthcare financial performance by segment ($m), FY 2010 72
Table 16: Hikal snapshot 76
Table 17: Hikal financial performance by segment ($m), FY 2010 78
Table 18: Shasun Pharmaceuticals Limited snapshot 82
Table 19: Shasun total sales ($m), FY 2010 84
Table 20: Shasun financial performance by key segment ($m), FY 2010 84
Table 21: Biocon snapshot 88
Table 22: Biocon financial performance by segment ($m), FY 2010 90
Table 23: Suven Life Sciences snapshot 94
Table 24: Suven financial performance by segment ($m), FY 2010 96
Table 25: Lupin (Novodigm) snapshot 99
Table 26: Intas snapshot 100
Table 27: Ranbaxy (now Daiichi Sankyo) snapshot 101
Table 28: Wockhardt snapshot 102
Table 29: Strides Arcolab snapshot 104
Table 30: Strides Arcolab financial performance by segment ($m), FY 2010 105
To order this report:
Pharmaceutical Industry: The Top 10 CMOs in India: Market dynamics, competitive positioning and trends
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article